Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1371563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A total of 7 patients with clinical stage C prostate cancer determined by digital rectal examination, transrectal ultrasonography, radionuclide bone scanning and serum prostatic acid phosphatase determination was treated with luteinizing hormone-releasing hormone analogues for 2 to 5 months in an attempt to downstage the disease. Although substantial decreases in prostate specific antigen level and prostatic volume occurred, only 2 patients experienced pathological downstaging of disease. We conclude that luteinizing hormone-releasing hormone therapy for downstaging of clinical stage C prostatic cancer is of limited value.
Medical subject headings
- Gonadotropin-Releasing Hormone
- Prostatic Neoplasms